or doxorubicin with dexrazoxane (n = 105; 81 analyzed). Echocardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide ...

One death owing to doxorubicin cardiomyopathy Slightly greater cardiotoxicity (2%) in Q3w group vs Q2w group (1%) [27] Martin et al. BCIRG 001 FAC × 6 vs TAC × 6 1491 55 CHF: 1.6% (DAC ...

The echocardiographic results showed that the group subjected to exosomes recovered from doxorubicin-induced cardiomyopathy showing improved both left ventricle fraction and ejection fraction. Also, ...

Adriamycin (doxorubicin hydrochloride ... Morphological changes in the ADR group were typical for adriamycin-induced cardiomyopathy and included swelling of mitochondria, vacuolization of the ...

Treating survivors with asymptomatic left ventricular dysfunction with enalapril delays, but does not prevent, progressive anthracycline cardiomyopathy. 15,42 It remains unclear whether preclinical ...

RP-A601 was generally well-tolerated at a dose of 8.0E13 GC/kg with no dose-limiting toxicities in all three patients with up to 12 months follow-up RP-A601 promoted increased protein expression ...

Hypertrophic cardiomyopathy (HCM) is a condition that thickens some of the heart’s muscles, making it harder to pump blood. Hypertrophic cardiomyopathy (HCM) usually affects the ventricular ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

– Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin – – Additional 42-Month ...

These data will be featured in a poster entitled, “A Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy,” being presented by Giri Murlidharan, Ph.D., Senior ...